PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pfizer (PFE) PT Raised to $42 at Deutsche Bank Following 4Q
January 31, 2018 7:39 AM ESTDeutsche Bank raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $41.00) while maintaining a Buy rating following 4Q. PFE reported 4Q EPS of $0.62, well above consensus of $0.56. Revenue came in just above estimates, while gross margin was lower and operating expenses were... More
Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
January 30, 2018 6:46 AM EST(Updated - January 30, 2018 6:49 AM EST)
Pfizer (NYSE: PFE) reported Q4 EPS of $0.62, $0.06 better than the analyst estimate of $0.56. Revenue for the quarter came in at $13.7 billion versus the consensus estimate of $13.68 billion.
Pfizers 2018 financial guidance is presented below. Financial guidance reflects... More
